Skip to main content
Premium Trial:

Request an Annual Quote

Gen9, SynbiCite Partner on Access to Gene Synthesis for Synthetic Biology

NEW YORK (GenomeWeb) – DNA construction firm Gen9 and British synthetic biology network SynbiCite have announced a partnership to increase access to gene synthesis technology.

Under the terms of the agreement, SynbiCite members will have access to Gen9's BioFab high-throughput gene synthesis platform.

Financial and other details of the agreement were not disclosed.

"Gen9's DNA synthesis technologies will be an invaluable resource to our members," John Collins, SynbiCite's commercial director, said in a statement. "These types of industry partnerships enable faster commercialization of breakthrough technologies in the space."

Cambridge, Massachusetts-based Gen9 said in a statement that it offers high-quality, low-cost DNA constructs on large scales.

SynbiCite is a network that aims to grow the synthetic biology industry in the UK by connecting research and commercial entities. It's based at Imperial College London and funded by £28 million ($40.1 million) in grants from the UK Research Councils, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, Innovate UK, and its industrial and academic partners.

The deal is Gen9's latest to promote its DNA synthesis platform. Last fall, the firm signed a partnership with digital lab notebook maker Benchling on an integrated DNA library design feature, and it inked a deal to provide DNA parts to the International Genetically Engineered Machine Competition.